◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PRTA

Prothena Corporation plc (PRTA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-02

Prothena Corporation plc (PRTA) operates in the BIOTECHNOLOGY industry and is headquartered in Dublin, Ireland with about 67 employees. Its market capitalization is roughly $435 million. In the fiscal year ended 2025-12-31, PRTA reported $10M in revenue and ($244M) in net income.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.

Interactive charts & full statements → Open the PRTA valuation workbench →

PRTA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Revenue	$55M	$10M	$135M	$91M	$54M	$201M	$1M	$1M	$1M	$28M	$1M	$2M	$51M	$1M	$3M	$1M	$1M
Gross Profit	$24M	$6M	$135M	$91M	$54M	$201M	$1M	($50M)	($100M)	$28M	$1M	$2M	$51M	$1M	$3M	$1M	$1M
Gross Margin %	43.5%	61.8%	100.0%	100.0%	100.0%	100.0%	100.0%	-6145.2%	-10495.1%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($63M)	($185M)	($155M)	($191M)	($132M)	$72M	($113M)	($86M)	($159M)	($155M)	($160M)	($80M)	($7M)	($40M)	($41M)	($29M)	($12M)
Operating Margin %	-115.1%	-1905.8%	-114.4%	-209.1%	-244.1%	35.9%	-13216.2%	-10527.9%	-16634.0%	-564.2%	-15121.8%	-4974.3%	-13.1%	-5980.3%	-1557.9%	-5768.1%	-978.4%
Net Income	($44M)	($244M)	($122M)	($147M)	($117M)	$67M	($111M)	($78M)	($156M)	($153M)	($160M)	($81M)	($7M)	($41M)	($41M)	($30M)	($12M)
Net Margin %	-80.7%	-2520.6%	-90.5%	-160.9%	-217.0%	33.4%	-13029.8%	-9542.6%	-16297.9%	-556.8%	-15176.1%	-5016.3%	-14.1%	-6064.5%	-1558.0%	-5852.1%	-1004.2%
EBITDA	($41M)	($197M)	($128M)	($160M)	($131M)	$79M	($106M)	($84M)	($153M)	($152M)	($157M)	($79M)	($6M)	($40M)	($41M)	($29M)	($12M)
Earnings Per Share (EPS)	$-0.83	$-4.53	$-2.27	$-2.76	$-2.47	$1.38	$-2.78	$-1.95	$-3.93	$-4.07	$-4.66	$-2.66	$-0.29	$-2.20	$-2.84	$-1.68	$-0.71
Shares Outstanding (M)	52M	54M	54M	53M	47M	48M	40M	40M	40M	38M	34M	30M	25M	19M	15M	18M	18M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRTA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$1M	$51M	$0M	$2M	$4M	$3M	$2M	$1M
Gross Profit	$1M	$50M	($1M)	($27M)	$4M	$3M	$2M	$1M
Gross Margin %	100.0%	98.2%	-4385.7%	-1098.3%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($21M)	$26M	($27M)	($40M)	($85M)	($66M)	($65M)	($67M)
Operating Margin %	-2089.2%	50.5%	-129576.2%	-1666.3%	-1914.4%	-2319.0%	-3056.8%	-6857.0%
Net Income	($19M)	$33M	($22M)	($37M)	($126M)	($60M)	($58M)	($59M)
Net Margin %	-1839.9%	64.0%	-102804.8%	-1513.1%	-2845.4%	-2128.5%	-2729.9%	-6082.6%
EBITDA	($18M)	$34M	($21M)	($36M)	($52M)	($61M)	($59M)	($60M)
Earnings Per Share (EPS)	$-0.36	$0.60	$-0.40	$-0.68	$-2.34	$-1.12	$-1.08	$-1.10
Shares Outstanding (M)	52M	54M	54M	54M	54M	54M	54M	54M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRTA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Cash from Operations (CFO)	($60M)	($164M)	($150M)	($134M)	($109M)	$93M	($80M)	($53M)	($28M)	($131M)	($117M)	($62M)	($1M)	($32M)	($42M)	($20M)	($9M)
Capital Expenditures (CapEx)	$1M	$0M	$0M	$3M	$0M	$1M	$0M	$1M	$2M	$4M	$17M	$1M	$1M	$1M	$1M	$1M	$3M
Free Cash Flow (FCF)	($61M)	($164M)	($150M)	($137M)	($109M)	$92M	($81M)	($54M)	($30M)	($135M)	($134M)	($64M)	($1M)	($33M)	($43M)	($20M)	($12M)
FCF Margin %	-111.3%	-1690.6%	-111.2%	-149.6%	-202.7%	45.9%	-9444.1%	-6575.4%	-3146.0%	-489.9%	-12693.2%	-3972.4%	-2.4%	-4831.7%	-1631.8%	-4002.4%	-940.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRTA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($25M)	$29M	($23M)	($41M)	($46M)	($53M)	($48M)	($45M)
Capital Expenditures (CapEx)	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($26M)	$29M	($23M)	($41M)	($46M)	($53M)	($48M)	($45M)
FCF Margin %	-2544.7%	56.5%	-111019.2%	-1680.1%	-1050.4%	-1888.4%	-2252.2%	-4659.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRTA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Assets	$303M	$327M	$547M	$696M	$758M	$609M	$333M	$419M	$499M	$496M	$460M	$385M	$304M	$182M	$129M	$4M	$3M
Cash & Cash Equivalents	$288M	$308M	$471M	$619M	$710M	$579M	$295M	$376M	$428M	$418M	$387M	$371M	$294M	$177M	$125M	—	—
Total Liabilities	$16M	$46M	$60M	$135M	$136M	$143M	$149M	$146M	$176M	$89M	$95M	$25M	$14M	$9M	$3M	$10M	$3M
Total Debt (Short + Long-Term)	$3M	$3M	$3M	$1M	$6M	$6M	$6M	$5M	$2M	$36M	$90M	$51M	$51M	$51M	$0M	$0M	$0M
Total Shareholders' Equity	$287M	$280M	$487M	$561M	$622M	$466M	$184M	$273M	$323M	$407M	$365M	$361M	$290M	$173M	$126M	($6M)	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRTA viewer.

Other Companies in BIOTECHNOLOGY

PHAT · Phathom Pharmaceuticals Inc — $467 million
ARVN · Arvinas Inc — $464 million
EPRX · Eupraxia Pharmaceuticals Inc. Common Stock — $451 million
BLSM · BlossomHill Therapeutics, Inc. Common Stock — $437 million
CRMD · CorMedix Inc — $433 million
PROK · ProKidney Corp. — $427 million
CCCC · C4 Therapeutics Inc — $415 million
ASMB · Assembly Biosciences Inc — $410 million

← PRT All “P” companies PRTC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.